Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo
Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo
复制标题
DOI：
10.1093/jnci/dji314
复制
发表时间：
2005-10-19
影响因子：
10.3
通讯作者：
Hasan, T
中科院分区：
文献类型：
--
作者：
del Carmen, MG;Rizvi, I;Hasan, T
背景资料。上皮性卵巢癌往往对标准治疗产生抵抗力，这是与该疾病相关的高死亡率的主要原因。我们检测了联合免疫疗法和光动力疗法(PDT)治疗卵巢癌的疗效。免疫疗法阻断表皮生长因子受体(EGFR)的活性，EGFR的过度表达与耐药卵巢癌的发生有关。光动力疗法是一种基于机制的光化学疗法，对化疗和放射抵抗的卵巢肿瘤有效。方法：我们在人卵巢癌小鼠模型中测试了由C225(一种抑制EGFR受体酪氨酸激酶活性的单抗)和基于苯并卟啉衍生单酸A(BPD)的PDT组成的联合方案。在每组使用9-19只小鼠的急性治疗反应和生存研究中评估治疗效果。数据分析采用方差分析和Wilcoxon统计方法。结果：与未治疗对照组相比，PDT+C225组小鼠的平均肿瘤负荷最低(平均肿瘤负荷百分比=9.8%，95%可信区间[CI]=2.3%~17.3%，P
Background. Epithelial ovarian cancer often develops resistance to standard treatments, which is a major reason for the high mortality associated with the disease. We examined the efficacy of a treatment regimen that combines immunotherapy to block the activity of epidermal growth factor receptor (EGFR), overexpression of which is associated with the development of resistant ovarian cancer, and photodynamic therapy (PDT), a mechanistically distinct photochemistrybased modality that is effective against chemo- and radioresistant ovarian tumors.Methods: We tested a combination regimen consisting of C225, a monoclonal antibody that inhibits the receptor tyrosine kinase activity of EGFR, and benzoporphyrin derivative monoacid A (BPD)-based PDT in a mouse model of human ovarian cancer. Therapeutic efficacy was evaluated in acute treatment response and survival studies that used 9-19 mice per group. Analysis of variance and Wilcoxon statistics were used to analyze the data. All statistical tests were two-sided.Results: Mice treated with PDT + C225 had the lowest mean tumor burden compared with that in the no-treatment control mice (mean percent tumor burden = 9.8%, 95% confidence interval [CI] = 2.3% to 17.3%, P